Page last updated: 2024-09-03

ym 529 and Urinary Bladder Neoplasms

ym 529 has been researched along with Urinary Bladder Neoplasms in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fukata, S; Furihata, M; Inoue, K; Karashima, T; Kawada, C; Kurabayashi, A; Nomura, A; Ohtsuki, Y; Shuin, T	1
Kimura, S; Maekawa, T; Nogawa, M; Sato, K; Segawa, H; Yokota, A; Yuasa, T	1

Other Studies

2 other study(ies) available for ym 529 and Urinary Bladder Neoplasms

Article	Year
Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-15, Volume: 11, Issue:18 Topics: Acid Phosphatase; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Bone Resorption; Carcinoma, Transitional Cell; Cell Line; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Humans; Imidazoles; Immunohistochemistry; In Situ Nick-End Labeling; Isoenzymes; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoblasts; Proliferating Cell Nuclear Antigen; Tartrate-Resistant Acid Phosphatase; Taxoids; Tibia; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays	2005
A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. British journal of cancer, 2006, Nov-20, Volume: 95, Issue:10 Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carcinoma, Renal Cell; Cell Proliferation; Cisplatin; Diphosphonates; Drug Synergism; Drug Therapy, Combination; Female; Humans; Imidazoles; In Vitro Techniques; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Paclitaxel; Protein Prenylation; rap1 GTP-Binding Proteins; ras Proteins; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A	2006

Article

Year

Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-15, Volume: 11, Issue:18

Topics: Acid Phosphatase; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Bone Resorption; Carcinoma, Transitional Cell; Cell Line; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Humans; Imidazoles; Immunohistochemistry; In Situ Nick-End Labeling; Isoenzymes; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoblasts; Proliferating Cell Nuclear Antigen; Tartrate-Resistant Acid Phosphatase; Taxoids; Tibia; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays

2005

A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo.

British journal of cancer, 2006, Nov-20, Volume: 95, Issue:10

Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carcinoma, Renal Cell; Cell Proliferation; Cisplatin; Diphosphonates; Drug Synergism; Drug Therapy, Combination; Female; Humans; Imidazoles; In Vitro Techniques; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Paclitaxel; Protein Prenylation; rap1 GTP-Binding Proteins; ras Proteins; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A

2006